AUD13.73
3.31% day before yesterday
Australia, Nov 01, 06:10 am CET
ISIN
AU000000CUV3
Symbol
CUV
Sector
Industry

Clinuvel Pharmaceutical Stock price

AUD13.73
-0.79 5.44% 1M
-1.28 8.53% 6M
-2.22 13.90% YTD
-0.93 6.35% 1Y
-25.31 64.83% 3Y
-16.61 54.74% 5Y
+8.89 183.60% 10Y
Australia, Closing price Fri, Nov 01 2024
-0.47 3.31%
ISIN
AU000000CUV3
Symbol
CUV
Sector
Industry

Key metrics

Market capitalization AUD687.33m
Enterprise Value AUD504.34m
P/E (TTM) P/E ratio 19.30
EV/FCF (TTM) EV/FCF 16.02
EV/Sales (TTM) EV/Sales 5.72
P/S ratio (TTM) P/S ratio 7.79
P/B ratio (TTM) P/B ratio 3.39
Dividend yield 0.36%
Last dividend (FY24) AUD0.05
Revenue growth (TTM) Revenue growth 12.59%
Revenue (TTM) Revenue AUD88.18m
EBIT (operating result TTM) EBIT AUD43.55m
Free Cash Flow (TTM) Free Cash Flow AUD31.48m
EPS (TTM) EPS AUD0.71
P/E forward 18.19
P/S forward 7.00
EV/Sales forward 5.13
Show more

Is Clinuvel Pharmaceutical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

Clinuvel Pharmaceutical Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Clinuvel Pharmaceutical forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Clinuvel Pharmaceutical forecast:

Buy
100%

Financial data from Clinuvel Pharmaceutical

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
88 88
13% 13%
100%
- Direct Costs 30 30
27% 27%
34%
58 58
6% 6%
66%
- Selling and Administrative Expenses 11 11
5% 5%
12%
- Research and Development Expense 2.35 2.35
85% 85%
3%
45 45
7% 7%
51%
- Depreciation and Amortization 1.14 1.14
44% 44%
1%
EBIT (Operating Income) EBIT 44 44
6% 6%
49%
Net Profit 36 36
16% 16%
40%

In millions AUD.

Don't miss a Thing! We will send you all news about Clinuvel Pharmaceutical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.

Head office Australia
CEO Philippe Wolgen
Founded 1999
Website www.clinuvel.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today